Effects of Kuan-Sin-Yin decoction on immunomodulation and tumorigenesis in mouse tumor models

BMC Complementary and Alternative Medicine

Shu-Ling Fu²  Chung-Hua Hsu²  Hui-ping Tsai¹  Ching-Cheng Lin²  Tsai-Feng Li² 

[1] Herbal Medicine Product Technology Division of Biomedical Technology and Device Research Laboratories, Industrial Technology Research Institute, Hsinchu, Taiwan;Institute of Traditional Medicine, National Yang-Ming University, Taipei 11221, Taiwan

关键词: Kuan-Sin-Yin;    Cytostatic effect;    Immunomodulation;    Anti-cancer;    Traditional Chinese medicine;   

Others  :  1084877
DOI  :  10.1186/1472-6882-14-488

 received in 2014-09-22, accepted in 2014-12-11,  发布年份 2014

【 摘 要 】

Background

Complementary therapies are widely used among cancer patients. Kuan-Sin-Yin (KSY) decoction, a popular qi-promoting herbal medicine, was constituted with several herbs known to exhibit immunomodulating or anticancer activity. After combining these herbs as a compound formula, it is necessary to reassess the immunomodulation effects, the effects on tumor growth, and possible toxicity of KSY.

Methods

The anti-cancer effects of KSY in vivo were determined by measuring the tumor volumes, anticancer-associated cytokines (IFN-gamma, TNF-alpha, IL-2, and IL-12), accumulation of tumor infiltrating leukocytes (TILs), proliferation and apoptosis-related molecular markers (Ki-67, p53, p21, activated caspase 3, and cleaved PARP), and an in situ TUNEL assay. The body weight and serum chemistry of treated mice were also assessed. In vitro, the effects of KSY were evaluated using MTT assay, BrdU incorporation assay and cell growth curve.

Results

In vivo, KSY suppressed bladder or lung cancer growth but did not promote the production of cytokines nor increase the accumulation of TILs. The expression of p53 and p21 in KSY-treated mice were increased. The numbers of apoptotic tumor cells and the expression of apoptosis marker proteins (Caspase 3 and cleaved PARP) were not significantly elevated after KSY treatment. In vitro, the viability and proliferation of tumor cells, but not normal cells, were suppressed by KSY treatment. No significant toxicity was found in KSY-treated mice.

Conclusions

KSY suppressed the tumor growth in vivo and in vitro, which resulted from its cytostatic effects on cancer cells, rather than the induction of anti-cancer immunity. Under these experimental conditions, no apparent toxicity was observed.

【 授权许可】

   
2014 Li et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

【 参考文献 】

• [1]Zhuang SR, Chen SL, Tsai JH, Huang CC, Wu TC, Liu WS, Tseng HC, Lee HS, Huang MC, Shane GT, Yang CH, Shen YC, Yan YY, Wang CK: Effect of citronellol and the Chinese medical herb complex on cellular immunity of cancer patients receiving chemotherapy/radiotherapy. Phytother Res 2009, 23(6):785-790.
• [2]Zitvogel L, Tesniere A, Apetoh L, Ghiringhelli F, Kroemer G: [Immunological aspects of anticancer chemotherapy]. Bull Acad Natl Med 2008, 192(7):1469-1487. discussion 1487-1489
• [3]Anderson JG, Taylor AG: Use of complementary therapies for cancer symptom management: results of the 2007 National Health Interview Survey. J Altern Complement Med 2012, 18(3):235-241.
• [4]Verhoef MJ, Rose MS, White M, Balneaves LG: Declining conventional cancer treatment and using complementary and alternative medicine: a problem or a challenge? Curr Oncol 2008, 15(Suppl 2):s101-s106.
• [5]Konkimalla VB, Efferth T: Evidence-based Chinese medicine for cancer therapy. J Ethnopharmacol 2008, 116(2):207-210.
• [6]Mok TS, Yeo W, Johnson PJ, Hui P, Ho WM, Lam KC, Xu M, Chak K, Chan A, Wong H, Mo F, Zee B: A double-blind placebo-controlled randomized study of Chinese herbal medicine as complementary therapy for reduction of chemotherapy-induced toxicity. Ann Oncol 2007, 18(4):768-774.
• [7]McQuade JL, Meng Z, Chen Z, Wei Q, Zhang Y, Bei W, Palmer JL, Cohen L: Utilization of and attitudes towards traditional chinese medicine therapies in a chinese cancer hospital: a survey of patients and physicians. Evid Based Complement Alternat Med 2012, 2012:504507.
• [8]Chen FP, Chen TJ, Kung YY, Chen YC, Chou LF, Chen FJ, Hwang SJ: Use frequency of traditional Chinese medicine in Taiwan. BMC Health Serv Res 2007, 7:26. BioMed Central Full Text
• [9]Lee CJ, Cheng CH, Li YH, Liu CY, Hsu CH: A Chinese medicine, Kuan-Sin-Yin decoction, improves liver function in hepatitis B virus carriers: a randomized, controlled study. J Altern Complement Med 2013, 19(12):964-969.
• [10]Chang HH, Yeh CH, Sheu F: A novel immunomodulatory protein from Poria cocos induces Toll-like receptor 4-dependent activation within mouse peritoneal macrophages. J Agric Food Chem 2009, 57(14):6129-6139.
• [11]Spelman K, Burns J, Nichols D, Winters N, Ottersberg S, Tenborg M: Modulation of cytokine expression by traditional medicines: a review of herbal immunomodulators. Altern Med Rev 2006, 11(2):128-150.
• [12]Chen X, Zhang L, Cheung PC: Immunopotentiation and anti-tumor activity of carboxymethylated-sulfated beta-(1→3)-d-glucan from Poria cocos. Int Immunopharmacol 2010, 10(4):398-405.
• [13]Li J, Bao Y, Lam W, Li W, Lu F, Zhu X, Liu J, Wang H: Immunoregulatory and anti-tumor effects of polysaccharopeptide and Astragalus polysaccharides on tumor-bearing mice. Immunopharmacol Immunotoxicol 2008, 30(4):771-782.
• [14]Lin J, Dong HF, Oppenheim JJ, Howard OM: Effects of astragali radix on the growth of different cancer cell lines. World J Gastroenterol 2003, 9(4):670-673.
• [15]An HJ, Jeong HJ, Um JY, Park YJ, Park RK, Kim EC, Na HJ, Shin TY, Kim HM, Hong SH: Fructus Ligustrum lucidi inhibits inflammatory mediator release through inhibition of nuclear factor-kappaB in mouse peritoneal macrophages. J Pharm Pharmacol 2007, 59(9):1279-1285.
• [16]Jeong JC, Kim JW, Kwon CH, Kim TH, Kim YK: Fructus ligustri lucidi extracts induce human glioma cell death through regulation of Akt/mTOR pathway in vitro and reduce glioma tumor growth in U87MG xenograft mouse model. Phytother Res 2011, 25(3):429-434.
• [17]Sun YX: Immunological adjuvant effect of a water-soluble polysaccharide, CPP, from the roots of Codonopsis pilosula on the immune responses to ovalbumin in mice. Chem Biodivers 2009, 6(6):890-896.
• [18]Kang TH, Bang JY, Kim MH, Kang IC, Kim HM, Jeong HJ: Atractylenolide III, a sesquiterpenoid, induces apoptosis in human lung carcinoma A549 cells via mitochondria-mediated death pathway. Food Chem Toxicol 2011, 49(2):514-519.
• [19]Ye Y, Wang H, Chu JH, Chou GX, Chen SB, Mo H, Fong WF, Yu ZL: Atractylenolide II induces G1 cell-cycle arrest and apoptosis in B16 melanoma cells. J Ethnopharmacol 2011, 136(1):279-282.
• [20]He HL, Zhou XM, Wang Q, Zhao Y: Does the couse of astragalus-containing chinese herbal prescriptions and radiotherapy benefit to non-small-cell lung cancer treatment: a meta-analysis of randomized trials. Evid-Based Complent Alt Med 2013, 2013:426207.
• [21]Guo L, Bai SP, Zhao L, Wang XH: Astragalus polysaccharide injection integrated with vinorelbine and cisplatin for patients with advanced non-small cell lung cancer: effects on quality of life and survival. Med Oncol 2012, 29(3):1656-1662.
• [22]Zhuang SR, Chiu HF, Chen SL, Tsai JH, Lee MY, Lee HS, Shen YC, Yan YY, Shane GT, Wang CK: Effects of a Chinese medical herbs complex on cellular immunity and toxicity-related conditions of breast cancer patients. Br J Nutr 2012, 107(5):712-718.
• [23]Liao HF, Chen YJ, Yang YC: A novel polysaccharide of black soybean promotes myelopoiesis and reconstitutes bone marrow after 5-flurouracil- and irradiation-induced myelosuppression. Life Sci 2005, 77(4):400-413.
• [24]Lin YS, Huang LD, Lin CH, Huang PH, Chen YJ, Wong FH, Lin CC, Fu SL: In vitro and in vivo anticancer activity of a synthetic glycolipid as Toll-like receptor 4 (TLR4) activator. J Biol Chem 2011, 286(51):43782-43792.
• [25]Hung LC, Lin CC, Hung SK, Wu BC, Jan MD, Liou SH, Fu SL: A synthetic analog of alpha-galactosylceramide induces macrophage activation via the TLR4-signaling pathways. Biochem Pharmacol 2007, 73(12):1957-1970.
• [26]Hung SK, Hung LC, Kuo CD, Lee KY, Lee MS, Lin HY, Chen YJ, Fu SL: Andrographolide sensitizes Ras-transformed cells to radiation in vitro and in vivo. Int J Radiat Oncol Biol Phys 2010, 77(4):1232-1239.
• [27]Reagan-Shaw S, Nihal M, Ahmad N: Dose translation from animal to human studies revisited. FASEB J 2008, 22(3):659-661.
• [28]Mouse phenome database [http://phenome.jax.org/ webcite]
• [29]Zamarron BF, Chen W: Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci 2011, 7(5):651-658.
• [30]Liu JJ, Huang TS, Hsu ML, Chen CC, Lin WS, Lu FJ, Chang WH: Antitumor effects of the partially purified polysaccharides from Antrodia camphorata and the mechanism of its action. Toxicol Appl Pharmacol 2004, 201(2):186-193.
• [31]Lu H, Yang Y, Gad E, Wenner CA, Chang A, Larson ER, Dang Y, Martzen M, Standish LJ, Disis ML: Polysaccharide krestin is a novel TLR2 agonist that mediates inhibition of tumor growth via stimulation of CD8 T cells and NK cells. Clin Cancer Res 2011, 17(1):67-76.
• [32]Wang Z, Sun Y: Targeting p53 for novel anticancer therapy. Transl Oncol 2010, 3(1):1-12.
• [33]Li TM, Chen GW, Su CC, Lin JG, Yeh CC, Cheng KC, Chung JG: Ellagic acid induced p53/p21 expression, G1 arrest and apoptosis in human bladder cancer T24 cells. Anticancer Res 2005, 25(2A):971-979.
• [34]Kuang YF, Chen YH: Induction of apoptosis in a non-small cell human lung cancer cell line by isothiocyanates is associated with P53 and P21. Food Chem Toxicol 2004, 42(10):1711-1718.
• [35]Ryoma Y, Moriya Y, Okamoto M, Kanaya I, Saito M, Sato M: Biological effect of OK-432 (picibanil) and possible application to dendritic cell therapy. Anticancer Res 2004, 24(5C):3295-3301.
• [36]Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L: Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004, 56(2):185-229.
• [37]Carvajal LA, Manfredi JJ: Another fork in the road–life or death decisions by the tumour suppressor p53. EMBO Rep 2013, 14(5):414-421.
• [38]Chen S, Flower A, Ritchie A, Liu J, Molassiotis A, Yu H, Lewith G: Oral Chinese herbal medicine (CHM) as an adjuvant treatment during chemotherapy for non-small cell lung cancer: a systematic review. Lung Cancer 2010, 68(2):137-145.
• [39]Zhong LL, Chen HY, Cho WC, Meng XM, Tong Y: The efficacy of Chinese herbal medicine as an adjunctive therapy for colorectal cancer: a systematic review and meta-analysis. Complement Ther Med 2012, 20(4):240-252.